AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 32 min read$CLX

Clorox Co (CLX) (Q1 2027) Earnings Call Highlights: Record Cost Savings and GoJo

Clorox (CLX) reported Q1 2027 earnings, with CEO Linda Rendell and CFO Kevin Bellet discussing organic sales growth of 3.5% to 4.5%, including ERP benefits. They highlighted record cost savings, targeted pricing, and market share improvements in home care and Brita. GoJo synergies are progressing faster than expected, with revised EPS estimates. The company aims for long-term gross margin of 43% to 44% and operating margin of 18%.

Original reporting
finance.yahoo.com
Published Nov 3, 2026, 9:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Clorox Co (CLX) (Q1 2027) Earnings Call Highlights: Record Cost Savings and GoJo — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$CLXBullishHigh
01

Why it matters

The guidance lift and early synergy capture provide a fresh catalyst for the stock, likely prompting buying interest.

02

Market read

New earnings guidance and synergy estimates create a material trading opportunity for CLX.

03

What to watch

Potential supply‑chain disruptions or commodity price spikes could erode margin recovery.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Clorox's Q1 2027 earnings call highlighted record cost savings, integration progress on the GoJo acquisition, and updated organic sales guidance.

Company-level read

Ticker impact

$CLXBullishHigh confidence
Context

Clorox provided fresh FY2027 guidance with organic sales growth of 3.5%-4.5% and revised year‑one EPS impact to positive, plus $50 M of synergies.

Expected impact

likely upward pressure as investors price in higher margin outlook and early synergies.

Evidence & confidence

New guidance and synergy estimate are primary disclosures not previously reported, directly affecting valuation.

Market effects

Sector

Improved margin outlook may lift consumer‑staples peers.

Regional

U.S. consumer‑staples sector could see modest gains.

Global

Limited to U.S. markets; no broader macro effect.

Counterpoint

What could challenge this read

If cost synergies fall short, margin guidance may be overstated, risking a pull‑back.

Key entities

  • Executive
    Linda Rendell

    CEO of Clorox, discussed guidance and pricing strategy.

  • Executive
    Mark Bellet

    CFO of Clorox, detailed margin and synergy expectations.

Read at source← All news

StoryClorox posts 33% Q1 sales growth, EPS beat, but trims margin outlook amid cost inflation

Also covered by

5 outlets

Related articles

NOV 3
$CLXMed

Clorox Now Expects Earnings Near the Low End of Its Forecast as Costs Rise. Should Dividend Investors Be Worried?

Clorox (CLX) reported Q1 FY2027 results with net sales up 33% YoY to $1.91B, driven by Gojo acquisition and ERP transition. Adjusted EPS was $1.55, beating estimates. The company maintained annual guidance but expects earnings near the low end. Long-term debt rose 60% due to Gojo acquisition. Dividend yield is 5.6%, with 49 years of consecutive raises.

finance.yahoo.com6 min
NOV 3
$CLXMedAI 8/10

Why is Clorox stock climbing today?

Clorox (CLX) stock rose 1.2% in pre-market trading after reporting fiscal Q1 earnings of $1.55 per share, beating estimates by 45%, with revenue of $1.91B. Sales increased 33% YoY, driven by the GOJO acquisition and organic growth. Analysts upgraded price targets (Evercore ISI to $99, Wells Fargo to $90, JPMorgan to $86), but Goldman Sachs maintained a Sell rating with a $74 target. Management warned of higher input costs and adjusted EPS guidance downward.

investing.com5 min
NOV 3
$CLXMed

Clorox (CLX) Q1 2027 Earnings Call Transcript

Clorox (CLX) reported Q1 2027 earnings, updating its outlook to reflect $240M in input cost inflation, driven by commodities and transportation. The company expects organic sales growth of 3.5% to 4.5% for the year, with a flat to slightly positive performance in the back half. Clorox also announced Fabian Garcia as its next CEO, effective January. The company is implementing cost savings and targeted pricing to mitigate inflationary pressures.

finance.yahoo.com2 min
NOV 3
$CLXMed

Clorox Q1 Earnings Call Highlights

Clorox (CLX) maintained its fiscal-year organic-sales-growth outlook of 3.5% to 4.5%, with Q2 expected to range from flat to down 2%. The company reported share gains in home care, Brita, and Hidden Valley Ranch, while Kingsford and cat litter faced challenges. Clorox is prioritizing pricing, innovation, and GOJO integration, with Fabian Garcia appointed as the next CEO. The company expects positive adjusted EPS impact from synergies in fiscal 2027.

finance.yahoo.com2 min